Effects of combined beta-adrenergic and cholinergic blockade on the initial ventilatory response to exercise in humans.
To elucidate whether combined adrenergic and parasympathetic blockade would affect the ventilatory response to exercise, especially at the initial stage (phase I), six healthy subjects performed a brief and light voluntary bilateral leg extension exercise and passive movements under the conditions of control (before the blockade) and after intravenous administration of combined beta-adrenergic (propranolol, 0.2 mg.kg-1) and muscarinic (atropine, 0.04 mg.kg-1) receptor antagonists. The movements were continued only within two breaths after the onset of the motion. Ventilation increased immediately and significantly (P < 0.05) within the first breath at the onset of voluntary exercise in all conditions as compared with at rest. However, the magnitude of increase in mean ventilation within two breaths at the start of exercise as against the resting value (delta ventilation) was significantly less (P < 0.05) after the combined blockades (2.5 l.min-1) than in the control condition (3.7 l.min-1). Passive movements showed a similar but smaller change as compared with voluntary exercise. The heart rate response to exercise was attenuated by the combined blockade while cardiac output showed a slight change at the onset of exercise. It is concluded that phase I should occur despite the inhibited activity of the beta-adrenergic and the cholinergic systems; nevertheless, the response was attenuated by the combined blockade. These results suggest a possible role of the beta-adrenergic and/or cholinergic systems in the rapid increase in ventilation that occurs at the start of exercise.
Ishida
K
K
Laboratory for Exercise Physiology, Research Center of Health, Physical Fitness and Sports, Nagoya University, Japan.
Hayashi
T
T
Moritani
T
T
Miyamura
M
M
D000319:Adrenergic beta-Antagonists; D000328:Adult; D001285:Atropine; D002302:Cardiac Output; D015444:Exercise / Q000502:physiology*; D006339:Heart Rate; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists; D011433:Propranolol; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D011950:Receptors, Cholinergic / Q000502:physiology; D012119:Respiration / Q000502:physiology*
D000319:Adrenergic beta-Antagonists; D018727:Muscarinic Antagonists; D011943:Receptors, Adrenergic, beta; D011950:Receptors, Cholinergic; D001285:Atropine; D011433:Propranolol